-
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
•
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM) medical service provider in its homeland in 2023, has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth and expansion strategy.…
-
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
•
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by an oversubscribed Series A financing of USD 411 million. The round was co-led by Forbion and General Atlantic, with additional investments from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. Product…
-
ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
•
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The collaboration is focused on the development of ImmVira’s engineered exosome anti-wrinkle products in the US and Canada. Partnership DetailsThe partnership aims to utilize ImmVira’s engineered exosome anti-wrinkle product as the core functional ingredient to upgrade…
-
SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies
•
On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement with Verdiva Bio, excluding Greater China and South Korea. Verdiva Bio is a clinical – stage global biopharmaceutical company focused on developing innovative therapies for obesity and other cardiovascular metabolic disorders. Collaboration DetailsThe collaboration includes…
-
MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201
•
Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) have entered into a collaboration and license agreement. MediLink’s TMALIN antibody drug conjugate (ADC) platform will be utilized to develop ZL-6201, a novel LRRC15-targeted ADC drug discovered by Zai Lab, for the treatment of solid…
-
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
•
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for its non-hormonal treatment elinzanetant has reached all primary endpoints. The study focused on moderate to severe vasomotor symptoms (VMS) caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing…
-
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
•
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA), has posted additional positive topline results from the Phase IIa study for IMG-007 in patients with moderate-to-severe atopic dermatitis (AD). The company also released results from a Phase I trial of IMG-007’s subcutaneous (SC) formulation.…
-
BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange
•
Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience and artificial intelligence (AI) technology for developing medical-grade digital therapy products, has successfully completed an initial public offering (IPO) of 181,112,000 shares on the Hong Kong Stock Exchange. The offering, priced at HKD 3.22 per…
-
NMPA Releases 89th Batch of Reference Drugs for GQCE Work
•
The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for generic quality consistency evaluation (GQCE) work. This batch aims to enhance the quality and consistency of generic drugs in the market. Batch DetailsThe 89th batch includes 51 new specifications and 28 specifications with modifications. The…
-
China’s NHC Aims for Over 90% Child-Friendly Hospitals by 2030
•
The Department of Maternal and Child Health Care of the National Healthcare Commission (NHC) has released the “Opinions on the Construction of Child-Friendly Hospitals,” setting a target for over 90% of medical institutions to become child-friendly by 2030. The initiative encourages grassroots medical and health institutions, such as township health…
-
Stryker to Acquire Inari Medical for USD 4.9 Billion to Boost VTE Pipeline
•
US-based Stryker (NYSE: SYK) has reached a definitive acquisition agreement with compatriot firm Inari Medical, Inc. (NASDAQ: NARI), purchasing all issued and outstanding shares at USD 80 per share in cash. The transaction amounts to a total fully diluted equity value of approximately USD 4.9 billion. Inari Medical’s PortfolioFounded in…
-
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
•
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection in China. The integrase strand transfer inhibitor (INSTI) was approved in May of last year for pre-exposure prophylaxis (PrEP) of HIV-1 in adults and adolescents (weighing ≥ 35kg) at risk of infection, to reduce the…
-
Insilico Medicine Raises USD 100 Million in Financing Round Led by Pudong and Hong Kong
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has reportedly raised USD 100 million in a new financing round. This marks the first joint investment effort between Shanghai’s Pudong district and Hong Kong in the biopharma sector. The initiative follows a partnership established in December 2023 between Shanghai Pudong Development…
-
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
•
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination,…
-
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
•
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs on the 2024 National Reimbursement Drug List (NRDL) following public feedback. These changes reflect the NHSA’s commitment to transparency and responsiveness in managing the country’s drug reimbursement policies. Specific Drug UpdatesThe NHSA has confirmed that…
-
Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities
•
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has announced his departure to seek external development opportunities, according to local media. His last day in the role will be January 14, 2025. Career Highlights at Eli Lilly ChinaDuring his tenure at Eli Lilly China,…
-
Fourier Intelligence Secures USD 109 Million in Series E Funding for Robotics Innovation
•
China-based Shanghai Fourier Intelligence Co., Ltd, a leading developer of exoskeleton robotic products for rehabilitation and orthoses, has reportedly raised close to RMB 800 million (USD 109 million) in a Series E financing round. The round was backed by prominent investors including Guoxin Investment, PDVC, Zhangjiang S&T Investment, Prosperity7, PEAKVEST,…
-
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products Administration (NMPA) for its Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) to treat adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination offers a new therapeutic option to patients in China,…
-
HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy
•
Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines Agency (EMA) for the Committee for Orphan Medicinal Products (COMP) on the orphan designation filing for its HG004. The gene therapy is designed for the treatment of inherited retinal dystrophy caused by dysfunction in the…
-
China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia
•
China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition Inc., obtaining development, regulatory filing, manufacturing, import, export, and commercialization rights to the Canadian firm’s Zunveyl (benzgalantamine delayed-release tablets). The drug targets mild to moderate dementia of Alzheimer’s disease (AD) and is approved for the…
